Memory loss claims must show repeated gabapentin exposure, a dementia or mild cognitive impairment diagnosis, and a failure to warn about that risk. Gabapentin is a prescription drug labeled for postherpetic nerve pain and add-on treatment for partial seizures. Product-liability lawsuits allege long-term use caused dementia and mild cognitive impairment and that makers did not warn doctors and patients. According to an Edgar Snyder & Associates case review, no federal multidistrict litigation consolidates these cases yet, so claims are investigated and filed as individual lawsuits.
Official resource:
- Read the official guidance from NIH — Use this primary source to verify the official guidance.
Table of Contents
- What are plaintiffs alleging?
- How much gabapentin use matters?
- Who is in the higher-risk group described in claims?
- What must a failure-to-warn claim prove?
- What records should potential claimants gather?
What are plaintiffs alleging?
Plaintiffs allege chronic gabapentin use caused lasting memory injury, not only brief forgetfulness. Mild cognitive impairment means measurable memory or thinking problems that do not yet prevent daily life. Dementia means more severe decline that interferes with independence.
The core claim is failure to warn. Plaintiffs say makers should have warned about dementia and cognitive-impairment risk and did not give doctors and patients adequate information. Federal labeling lists temporary memory loss and amnesia but contains no dementia warning cited in those claims, according to the U.S. National Library of Medicine medication guide.
How much gabapentin use matters?
Claimants must document repeated exposure. The key threshold discussed in litigation screening is six or more gabapentin prescriptions. In 26,414 matched adults with chronic low back pain followed from 2004 to 2024, six or more prescriptions were tied to 29 percent higher dementia diagnoses and 85 percent higher mild cognitive impairment diagnoses within 10 years, according to a BMJ Group research summary.
Prescription records, pharmacy logs, and diagnosis dates therefore matter more than a general memory complaint. Risk also rose with frequency. Patients with 12 or more prescriptions had about 40 percent higher dementia and 65 percent higher mild cognitive impairment rates than patients with 3 to 11 prescriptions.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Who is in the higher-risk group described in claims?
The study population was adults with chronic low back pain, not all gabapentin users. That limit matters because pain condition, age, and other drugs can affect memory.
Adults aged 18 to 64 showed more than double the associated dementia and impairment risk. Those adults are normally considered too young for dementia. That finding focuses claims beyond older adults and may shape medical review for early-onset diagnoses.
What must a failure-to-warn claim prove?
A plaintiff must practically show the maker knew or should have known the danger, owed a duty to warn, gave an inadequate warning, and that the defect caused injury and damages, according to Blizzard Greenberg failure-to-warn guidance. Each element needs separate proof. A diagnosis alone does not satisfy the test.
Causation is the hardest part. The gabapentin study is observational and cannot prove gabapentin caused dementia, even after researchers accounted for demographics, coexisting conditions, and other pain drugs. Defense lawyers will point to age, vascular disease, depression, sleep drugs, opioids, and other causes of memory loss.
What records should potential claimants gather?
Collect records before contacting a lawyer. Complete files allow faster screening and medical review.
- Pharmacy printout showing every gabapentin fill, dose, and date
- Prescriber notes showing why gabapentin was started and continued
- Neurology records documenting mild cognitive impairment or dementia testing
- List of other sedating, pain, and psychiatric drugs with dates used
- Work, school, or family records showing change in memory and function
You Might Also Like
- Uber Sexual Assault Lawsuit: Where the MDL Stands in 2026
- Who Qualifies for a Gabapentin Dementia Lawsuit Claim?
- Gabapentin Dementia Lawsuit Eligibility Criteria